On January27, 2023, the  (FDA)  Food and Drug Administration approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, which is a great news.

Million pharmaceutical focuses on new drug api development and becomes only elacestrant stock manufacture. We also complete the full tech pack of elacestrant api and intermediates.